It has also been suggested that a combination of PARP1 inhibitors with immunotherapies may also be an effective combination treatment for lung cancers, particularly in tumors with other DNA repair defects, such as ERCC1 deficiency (117). This evidence concerns the gene PARP1 and lung cancer.